3月23日 - ** 制药商Viatris VTRS.O股价盘前上涨2%至13.47美元
** 该公司称日本批准其药物Effexor用于治疗广泛性焦虑症
** 该公司称，Effexor是日本首个获准用于治疗广泛性焦虑症的药物
** 艾菲克索（又名文拉法辛）已在日本获准用于治疗抑郁症--公司
** 在日本进行的一项后期研究显示，该药在八周后缓解焦虑症状的效果优于安慰剂，而且因副作用而退出研究的患者人数有限--公司
** 该药物已在日本以外的 80 多个国家被批准用于治疗焦虑症 - VTRS
** 截至上次收盘，该公司股价年累计上涨约 6%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.